Naringenin relieves paclitaxel‐induced pain by suppressing calcitonin gene‐related peptide signalling and enhances the anti‐tumour action of paclitaxel

Naringenin's anti-nociceptive mechanism involves CGRP signalling and neuroimmunoregulation. Furthermore, naringenin facilitates paclitaxel's anti-tumour action, possibly involving apoptosis. This study demonstrates naringenin's potential as a supplementary treatment in cancer therapy by mitigating side effects and potentiating efficacy of chemotherapy.